First Patient Enrolled for the Investigator-Initiated trial of Zhaoke Ophthalmology’s ZKY001, for the Treatment of Neurotrophic Keratitis

Zhaoke Ophthalmology Named as a “China Top 30 Innovative Small Molecule Drug Developer” on the “2020 China Top 100 Innovative Biotech Companies List”

Podcast Series Episode 4: Glaucoma and Zhaoke Ophthalmology's New Treatments

Zhaoke Ophthalmology Named as a “China Top 30 Innovative Small Molecule Drug Developer” on the “2020 China Top 100 Innovative Biotech Companies List”

Zhaoke Ophthalmology’s IND Application for Potential First Myopia Drug to Market in China and Globally, NVK-002, Approved for Phase III Clinical Trial by the CDE